Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy-Reference-Cited by-同舟云学术

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy

Published:2017-08-01 Issue:8 Volume:22 Page:1281
ISSN:1420-3049
Container-title:Molecules
language:en
Short-container-title:Molecules

Author:

Chen Hao,Lin Zongtao,Arnst Kinsie,Miller Duane^ORCID,Li Wei

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Link

http://www.mdpi.com/1420-3049/22/8/1281/pdf

Reference150 articles.

1. A History of Cancer Chemotherapy

2. Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

3. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

4. Recent advances of novel targeted therapy in non-small cell lung cancer

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads;European Journal of Medicinal Chemistry;2024-10

2. Research progress of antibody–drug conjugates in gynecologic cancer;Holistic Integrative Oncology;2024-08-29

3. Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer;JCO Precision Oncology;2024-08

4. Design and Synthesis of Some New Benzimidazole-1,2,3-triazole-thiazolidine-2,4-dione Conjugates as Tubulin Polymerization Inhibitors;Russian Journal of Bioorganic Chemistry;2024-08

5. Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities;Pharmaceutical Science Advances;2024-08